Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis

PPAR Research

Volumn 2016, Issue , 2016, Pages

  Ferret Sena, Véronique ^a   Maia E Silva, Alexandra ^a   Sena, Armando ^a,b   Cavaleiro, Inês ^a   Vale, José ^c   Derudas, Bruno ^d   Chinetti Gbaguidi, Giulia ^d,e   Staels, Bart ^d  

^a INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

^b HOSPITAL DOS CAPUCHOS   (Portugal)

^c Hospital Beatriz Angelo   (Portugal)

^d UNIV LILLE   (France)

^e UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CD36 ANTIGEN; CYCLOPHILIN; GELATINASE B; INTERFERON BETA SERINE; MESSENGER RNA; NATALIZUMAB; NEOPTERIN; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 85008932663     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2016/5716415     Document Type: Article

References (20)

1. E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels, "Regulation of macrophage functions by PPAR-α, PPAR-γ, and LXRs in mice and men," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1050-1059, 2008.
2. S. E. Dunn, S. Ousman, A. R. Sobel et al., "Peroxisome Proliferator-Activated Receptor (PPAR) α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity," The Journal of Experimental Medicine, vol. 204, no. 2, pp. 321-330, 2007.
3. S. E. Dunn, R. Bhat, D. S. Straus et al., "Peroxisome proliferatoractivated receptor δ limits the expansion of pathogenic Thcells during central nervous system autoimmunity," The Journal of Experimental Medicine, vol. 207, no. 8, pp. 1599-1608, 2010.
4. S. Hucke, J. Floßdorf, B. Grützke et al., "Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ," Brain, vol. 135, no. 5, pp. 1586-1605, 2012.
5. L. Klotz, M. Schmidt, T. Giese et al., "Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor γ levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients," Journal of Immunology, vol. 175, no. 8, pp. 4948-4955, 2005.
6. C. C. Kaiser, D. K. Shukla, G. T. Stebbins et al., "A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis," Journal of Neuroimmunology, vol. 211, no. 1-2, pp. 124-130, 2009.
7. M. Jana, S. Mondal, F. J. Gonzalez, and K. Pahan, "Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β," Journal of Biological Chemistry, vol. 287, no. 41, pp. 34134-34148, 2012.
8. M. Khademi, L. Bornsen, F. Rafatnia et al., "The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers," European Journal of Neurology, vol. 16, no. 4, pp. 528-536, 2009.
9. P. Kivisäkk, B. C. Healy, V. Viglietta et al., "Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells," Neurology, vol. 72, no. 22, pp. 1922-1930, 2009.
10. K. Kimura, M. Nakamura, W. Sato et al., "Disrupted balance of T cells under natalizumab treatment in multiple sclerosis," Neurology® Neuroimmunology & Neuroinflammation, vol. 3, no. 2, p. e210, 2016.
11. A. Sena, K. Bendtzen, M. J. Cascais, R. Pedrosa, V. Ferret-Sena, and E. Campos, "Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta," Journal of Neurology, vol. 257, no. 10, pp. 1703-1707, 2010.
12. P. Iaffaldano, M. Ruggieri, R. G. E. Viterbo, M. Mastrapasqua, and M. Trojano, "The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis," Brain, behavior, and immunity, vol. 35, pp. 176-181, 2014.
13. W. Han, H. Zhao, B. Jiao, and F. Liu, "EPA and DHA increased PPARγ expression and deceased integrin-linked kinase and integrin β1 expression in rat glomerular mesangial cells treated with lipopolysaccharide," BioScience Trends, vol. 8, no. 2, pp. 120-125, 2014.
14. L. Szalardy, D. Zadori, E. Tanczos et al., "Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis," Neuroscience Letters, vol. 554, pp. 131-134, 2013.
15. T. Adhikary, A. Wortmann, T. Schumann et al., "The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state," Nucleic Acids Research, vol. 43, no. 10, pp. 5033-5051, 2015.
16. M. Comabella, I. Pericot, R. Goertsches et al., "Plasma osteopontin levels in multiple sclerosis," Journal of Neuroimmunology, vol. 158, no. 1-2, pp. 231-239, 2005.
17. Y. Oyama, N. Akuzawa, R. Nagai, and M. Kurabayashi, "PPARγ ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells," Circulation Research, vol. 90, no. 3, pp. 348-355, 2002.
18. T. Nakamachi, T. Nomiyama, F. Gizard et al., "PPARα agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes," Diabetes, vol. 56, no. 6, pp. 1662-1670, 2007.
19. A. Brown, "Osteopontin: a key link between immunity, inflammation and the central nervous system," Translational Neuroscience, vol. 3, no. 3, pp. 288-293, 2012.
20. W. Huang, G. B. Rha, M.-J. Han et al., "PPARα and PPARγ effectively protect against HIV-induced inflammatory responses in brain endothelial cells," Journal of Neurochemistry, vol. 107, no. 2, pp. 497-509, 2008.